for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NGM Biopharmaceuticals Inc

NGM.OQ

Latest Trade

16.40USD

Change

0.73(+4.66%)

Volume

58,790

Today's Range

15.69

 - 

16.55

52 Week Range

8.81

 - 

23.93

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.67
Open
15.69
Volume
58,790
3M AVG Volume
4.23
Today's High
16.55
Today's Low
15.69
52 Week High
23.93
52 Week Low
8.81
Shares Out (MIL)
68.83
Market Cap (MIL)
1,078.53
Forward P/E
-10.96
Dividend (Yield %)
--

Next Event

Q3 2020 NGM Biopharmaceuticals Inc Earnings Release

Latest Developments

More

NGM Bio Presents Findings From 24-Week Phase 2 Study (Cohort 4) Of Aldafermin And Announces Enrollment Completed In Phase 2B Alpine 2/3 Study

NGM Bio Reports Qtrly Loss Per Share Of $0.38

NGM Biopharmaceuticals Files For Mixed Shelf Of Upto $400 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The Company’s product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively activating fibroblast growth factor receptor 1c-beta-klotho and has the potential as an insulin sensitizer for the treatment of type two diabetes and NASH. NGM386 and NGM395 are engineered variants of the human hormone known as GDF15, which is developed for the treatment of obesity. NGM120 is an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, and cancer.

Industry

Biotechnology & Drugs

Contact Info

333 Oyster Point Blvd

SOUTH SAN FRANCISCO, CA

94080-1978

United States

+1.650.2435555

https://www.ngmbio.com/

Executive Leadership

William J. Rieflin

Executive Chairman of the Board of Directors

David J. Woodhouse

Chief Executive Officer, Director

Jin-Long Chen

Founder, Chief Scientific Officer, Director

Siobhan Nolan Mangini

Chief Financial Officer

Valerie L. Pierce

Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.1K

2020(E)

0.1K
EPS (USD)

2019

-0.850

2020(E)

-1.478
Price To Earnings (TTM)
--
Price To Sales (TTM)
11.15
Price To Book (MRQ)
3.58
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-21.32
Return on Equity (TTM)
-19.24

Latest News

Latest News

BRIEF-Ngm Biopharmaceuticals Files Prospectus Related To Offering Of Common Stock Of Upto $150 Mln - SEC Filing

* NGM BIOPHARMACEUTICALS FILES PROSPECTUS RELATED TO OFFERING OF COMMON STOCK OF UPTO $150 MILLION - SEC FILING Source text: https://bit.ly/3hyZ16O Further company coverage:

BRIEF-NGM Biopharmaceuticals Files For Mixed Shelf Of Upto $400 Million

* NGM BIOPHARMACEUTICALS FILES FOR MIXED SHELF OF UPTO $400 MILLION - SEC FILING Source text: (https://bit.ly/30eJNOe) Further company coverage:

BRIEF-NGM Bio Appoints Siobhan Nolan Mangini As CFO

* NGM BIO APPOINTS SIOBHAN NOLAN MANGINI AS CHIEF FINANCIAL OFFICER

BRIEF-NGM Biopharmaceuticals Posts Quarterly Loss Per Share $0.28

* NGM BIO PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-NGM Bio Reports Q4 Net Loss Per Share Of $0.24

* NGM BIO REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-Aetna Trombley To Step Down As President And COO Of NGM Biopharma

* AETNA WUN TROMBLEY, PH.D. TO STEP DOWN AS PRESIDENT AND CHIEF OPERATING OFFICER OF NGM BIO TO ASSUME CHIEF EXECUTIVE OFFICER ROLE AT UNDISCLOSED PRIVATELY HELD COMPANY

BRIEF-NGM Bio Announces Positive Preliminary Topline Liver Histology And Biomarker Data From 24-Week Phase 2 Study Of Aldafermin In Nash Patients

* NGM BIO ANNOUNCES POSITIVE PRELIMINARY TOPLINE LIVER HISTOLOGY AND BIOMARKER DATA FROM 24-WEEK PHASE 2 STUDY (COHORT 4) OF ALDAFERMIN IN NASH PATIENTS, INCLUDING STATISTICALLY SIGNIFICANT ACHIEVEMENT OF COMPOSITE ENDPOINT OF BOTH FIBROSIS IMPROVEMENT AND RESOLUTION OF...

BRIEF-Ngm Bio Begins Early-Stage Study Of Ngm120 For Cancer And Cancer Anorexia/Cachexia Syndrome

* NGM BIO ANNOUNCES INITIATION OF PHASE 1A/1B CLINICAL STUDY OF NGM120 FOR THE POTENTIAL TREATMENT OF CANCER AND CANCER ANOREXIA/CACHEXIA SYNDROME (CACS) Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up